Invention Grant
- Patent Title: Crystalline FGFR4 inhibitor compound and uses thereof
-
Application No.: US15566527Application Date: 2016-04-13
-
Publication No.: US10562888B2Publication Date: 2020-02-18
- Inventor: George Moniz , Kristen Sanders , Arani Chanda , Kenshi Yoshida
- Applicant: Eisai R&D Management Co., Ltd.
- Applicant Address: JP Tokyo
- Assignee: Eisai R&D Management Co., LTD.
- Current Assignee: Eisai R&D Management Co., LTD.
- Current Assignee Address: JP Tokyo
- Agency: Buchanan Ingersoll & Rooney PC
- International Application: PCT/US2016/027334 WO 20160413
- International Announcement: WO2016/168331 WO 20161020
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A61K31/505

Abstract:
A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.
Public/Granted literature
- US20180093972A1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF Public/Granted day:2018-04-05
Information query